Corestem Overview

  • Founded
  • 2003

  • Status
  • Public

  • Employees
  • 392

  • Stock Symbol
  • 166480

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $6.26

  • (As of Thursday Closing)

Corestem General Information


Corestemchemon Inc formerly Corestem Inc is a South Korea based company biopharmaceutical company. It is primarily engaged in the business activity of developing and producing stem cell therapy for the treatment of incurable diseases. The company's NEURONATA-R inj., a stem cell therapy, is for Lou Gehrig's disease which is a rare incurable disease. In addition to the therapy of Lou Gehrig's disease, it also has a pipeline of therapies for various diseases such as lupus, multiple system atrophy, and osteoarthritis.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Stock Exchange
Primary Office
  • Number 1008, Number 902, Number 401 (the holy one, SK Techno Building)
  • 133-710 gu, holy days 55
  • Seoul, 04779
  • South Korea
+82 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Corestem Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.26 $6.11 $5.36 - $11.28 $157M 25.1M 75.1K -$0.26

Corestem Financials Summary

In Thousands,
TTM 31-Mar-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 153,026 142,465 235,874 291,120
Revenue 36,732 35,827 26,401 22,324
EBITDA 5,962 9,887 3,290 (10,647)
Net Income (4,766) (2,056) (6,110) (19,638)
Total Assets 71,531 62,248 114,627 130,964
Total Debt 17,752 14,598 23,226 18,479
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Corestem Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Corestem‘s full profile, request access.

Request a free trial

Corestem Executive Team (2)

Name Title Board Seat Contact Info
Kyung Suk Kim Co-Chief Executive Officer
Gyeong Suk Kim Executive
To view Corestem’s complete executive team members history, request access »

Corestem Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Corestem Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Corestem‘s full profile, request access.

Request a free trial

Corestem Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 01-Dec-2022 000000000 000.00 Laboratory Services (Healthcare)
To view Corestem’s complete investments history, request access »